Amedisys Operating Income vs Interest Income Analysis

AMED Stock

USD 91.79 0.63 0.69%

Amedisys financial indicator trend analysis is way more than just evaluating Amedisys prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Amedisys is a good investment. Please check the relationship between Amedisys Operating Income and its Interest Income accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Amedisys. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in income.

For information on how to trade Amedisys Stock refer to our How to Trade Amedisys Stock guide.

Operating Income vs Interest Income

Operating Income vs Interest Income Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Amedisys Operating Income account and Interest Income. At this time, the significance of the direction appears to have weak contrarian relationship.

The correlation between Amedisys' Operating Income and Interest Income is -0.02. Overlapping area represents the amount of variation of Operating Income that can explain the historical movement of Interest Income in the same time period over historical financial statements of Amedisys, assuming nothing else is changed. The correlation between historical values of Amedisys' Operating Income and Interest Income is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Operating Income of Amedisys are associated (or correlated) with its Interest Income. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Interest Income has no effect on the direction of Operating Income i.e., Amedisys' Operating Income and Interest Income go up and down completely randomly.

Correlation Coefficient

-0.02

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Operating Income

Operating Income is the amount of profit realized from Amedisys operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Amedisys is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.

Interest Income

Income earned from the investment of cash or from lending money to others, including interest from bank accounts, bonds, or other interest-bearing investments.

Most indicators from Amedisys' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Amedisys current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Amedisys. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in income.

For information on how to trade Amedisys Stock refer to our How to Trade Amedisys Stock guide.At present, Amedisys' Sales General And Administrative To Revenue is projected to increase slightly based on the last few years of reporting. The current year's Enterprise Value Over EBITDA is expected to grow to 16.65, whereas Discontinued Operations is forecasted to decline to (260.8 K).

	2021	2022	2023	2024 (projected)
Gross Profit	980.8M	962.8M	457.1M	447.4M
Total Revenue	2.2B	2.2B	2.2B	2.3B

Gross Profit Total Revenue

Amedisys fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Current Deferred Revenue	Common Stock Total Equity	Common Stock
Total Assets		0.96	-0.34	0.93	0.99	0.11	0.9	0.95	0.6	0.74	0.99	-0.37	0.74	0.95	0.35	0.96	0.29	0.72	-0.09	0.99	-0.16	0.95	0.9	0.76	0.52	0.53
Short Long Term Debt Total	0.96		-0.4	0.81	0.93	0.1	0.98	0.95	0.53	0.62	0.97	-0.42	0.62	0.86	0.2	1.0	0.27	0.73	-0.25	0.97	-0.29	0.85	0.89	0.72	0.38	0.39
Other Current Liab	-0.34	-0.4		-0.13	-0.36	-0.03	-0.48	-0.41	-0.42	0.08	-0.38	1.0	0.08	-0.28	-0.1	-0.41	-0.05	-0.35	0.16	-0.31	0.06	-0.2	-0.24	-0.44	-0.15	-0.15
Total Current Liabilities	0.93	0.81	-0.13		0.91	0.16	0.73	0.82	0.58	0.76	0.9	-0.16	0.76	0.91	0.42	0.82	0.44	0.52	0.05	0.93	-0.1	0.93	0.85	0.64	0.57	0.58
Total Stockholder Equity	0.99	0.93	-0.36	0.91		0.11	0.86	0.93	0.64	0.75	0.98	-0.38	0.75	0.97	0.41	0.93	0.23	0.75	-0.03	0.97	-0.11	0.95	0.88	0.76	0.57	0.58
Property Plant And Equipment Net	0.11	0.1	-0.03	0.16	0.11		0.14	-0.06	0.15	-0.13	0.17	-0.03	-0.13	0.02	0.46	0.08	0.19	0.32	0.47	0.12	-0.24	0.02	0.2	-0.04	0.46	0.46
Net Debt	0.9	0.98	-0.48	0.73	0.86	0.14		0.9	0.56	0.44	0.92	-0.5	0.44	0.78	0.19	0.97	0.28	0.68	-0.27	0.91	-0.29	0.74	0.83	0.63	0.37	0.37
Retained Earnings	0.95	0.95	-0.41	0.82	0.93	-0.06	0.9		0.47	0.69	0.94	-0.43	0.69	0.87	0.08	0.96	0.17	0.66	-0.39	0.94	-0.09	0.85	0.87	0.81	0.28	0.29
Accounts Payable	0.6	0.53	-0.42	0.58	0.64	0.15	0.56	0.47		0.17	0.6	-0.43	0.17	0.66	0.74	0.53	0.11	0.43	0.37	0.58	0.04	0.56	0.43	0.13	0.78	0.78
Cash	0.74	0.62	0.08	0.76	0.75	-0.13	0.44	0.69	0.17		0.69	0.05	1.0	0.76	0.12	0.63	0.09	0.54	-0.06	0.71	-0.16	0.85	0.7	0.74	0.26	0.28
Non Current Assets Total	0.99	0.97	-0.38	0.9	0.98	0.17	0.92	0.94	0.6	0.69		-0.4	0.69	0.92	0.35	0.97	0.25	0.75	-0.1	0.99	-0.17	0.91	0.88	0.75	0.52	0.53
Non Currrent Assets Other	-0.37	-0.42	1.0	-0.16	-0.38	-0.03	-0.5	-0.43	-0.43	0.05	-0.4		0.05	-0.3	-0.1	-0.43	-0.06	-0.37	0.17	-0.33	0.07	-0.22	-0.26	-0.46	-0.15	-0.15
Cash And Short Term Investments	0.74	0.62	0.08	0.76	0.75	-0.13	0.44	0.69	0.17	1.0	0.69	0.05		0.76	0.12	0.63	0.09	0.54	-0.06	0.71	-0.16	0.85	0.7	0.74	0.26	0.28
Net Receivables	0.95	0.86	-0.28	0.91	0.97	0.02	0.78	0.87	0.66	0.76	0.92	-0.3	0.76		0.46	0.87	0.27	0.64	0.04	0.93	-0.01	0.98	0.84	0.7	0.6	0.61
Common Stock Shares Outstanding	0.35	0.2	-0.1	0.42	0.41	0.46	0.19	0.08	0.74	0.12	0.35	-0.1	0.12	0.46		0.2	0.2	0.36	0.83	0.3	0.13	0.41	0.13	-0.04	0.96	0.96
Non Current Liabilities Total	0.96	1.0	-0.41	0.82	0.93	0.08	0.97	0.96	0.53	0.63	0.97	-0.43	0.63	0.87	0.2		0.26	0.72	-0.25	0.97	-0.28	0.85	0.87	0.73	0.39	0.39
Inventory	0.29	0.27	-0.05	0.44	0.23	0.19	0.28	0.17	0.11	0.09	0.25	-0.06	0.09	0.27	0.2	0.26		-0.16	0.11	0.35	-0.16	0.35	0.33	0.19	0.24	0.25
Other Current Assets	0.72	0.73	-0.35	0.52	0.75	0.32	0.68	0.66	0.43	0.54	0.75	-0.37	0.54	0.64	0.36	0.72	-0.16		0.1	0.67	-0.24	0.63	0.63	0.56	0.45	0.45
Other Stockholder Equity	-0.09	-0.25	0.16	0.05	-0.03	0.47	-0.27	-0.39	0.37	-0.06	-0.1	0.17	-0.06	0.04	0.83	-0.25	0.11	0.1		-0.14	-0.02	0.05	-0.19	-0.31	0.69	0.68
Total Liab	0.99	0.97	-0.31	0.93	0.97	0.12	0.91	0.94	0.58	0.71	0.99	-0.33	0.71	0.93	0.3	0.97	0.35	0.67	-0.14		-0.21	0.93	0.9	0.73	0.48	0.49
Property Plant And Equipment Gross	-0.16	-0.29	0.06	-0.1	-0.11	-0.24	-0.29	-0.09	0.04	-0.16	-0.17	0.07	-0.16	-0.01	0.13	-0.28	-0.16	-0.24	-0.02	-0.21		-0.1	-0.32	-0.12	0.1	0.09
Total Current Assets	0.95	0.85	-0.2	0.93	0.95	0.02	0.74	0.85	0.56	0.85	0.91	-0.22	0.85	0.98	0.41	0.85	0.35	0.63	0.05	0.93	-0.1		0.85	0.73	0.56	0.57
Short Term Debt	0.9	0.89	-0.24	0.85	0.88	0.2	0.83	0.87	0.43	0.7	0.88	-0.26	0.7	0.84	0.13	0.87	0.33	0.63	-0.19	0.9	-0.32	0.85		0.74	0.32	0.33
Current Deferred Revenue	0.76	0.72	-0.44	0.64	0.76	-0.04	0.63	0.81	0.13	0.74	0.75	-0.46	0.74	0.7	-0.04	0.73	0.19	0.56	-0.31	0.73	-0.12	0.73	0.74		0.15	0.16
Common Stock Total Equity	0.52	0.38	-0.15	0.57	0.57	0.46	0.37	0.28	0.78	0.26	0.52	-0.15	0.26	0.6	0.96	0.39	0.24	0.45	0.69	0.48	0.1	0.56	0.32	0.15		1.0
Common Stock	0.53	0.39	-0.15	0.58	0.58	0.46	0.37	0.29	0.78	0.28	0.53	-0.15	0.28	0.61	0.96	0.39	0.25	0.45	0.68	0.49	0.09	0.57	0.33	0.16	1.0

Click cells to compare fundamentals

Amedisys Account Relationship Matchups

Amedisys fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	1.3B	1.6B	1.9B	2.0B	2.1B	2.2B
Short Long Term Debt Total	326.1M	307.0M	545.6M	537.9M	487.2M	511.6M
Other Current Liab	(3.1M)	313.1M	(3.4M)	(20.1B)	382.9M	402.0M
Total Current Liabilities	326.9M	456.3M	374.3M	355.5M	473.7M	497.4M
Total Stockholder Equity	640.5M	809.2M	931.4M	1.1B	1.1B	1.1B
Property Plant And Equipment Net	112.9M	117.2M	119.7M	118.9M	130.8M	76.0M
Net Debt	295.8M	225.2M	502.9M	497.4M	341.4M	358.4M
Retained Earnings	246.4M	430.0M	639.1M	757.7M	747.9M	785.3M
Accounts Payable	31.3M	42.7M	38.2M	43.7M	28.2M	19.0M
Cash	30.3M	81.8M	42.7M	40.5M	145.9M	153.2M
Non Current Assets Total	912.2M	1.2B	1.5B	1.6B	1.6B	1.6B
Non Currrent Assets Other	18.9M	19M	19.9M	(20.4B)	(35.2M)	(37.0M)
Cash And Short Term Investments	30.3M	81.8M	42.7M	40.5M	145.9M	153.2M
Net Receivables	237.6M	255.1M	275.0M	296.8M	328.2M	344.6M
Common Stock Shares Outstanding	33.0M	33.3M	33.0M	32.7M	32.6M	23.4M
Liabilities And Stockholders Equity	1.3B	1.6B	1.9B	2.0B	2.1B	2.2B
Non Current Liabilities Total	294.3M	300.1M	506.4M	514.1M	466.7M	490.0M
Inventory	74.4M	11.8M	13.4M	25.2M	29.0M	30.5M
Other Current Assets	8.2M	13.3M	25.6M	26.4M	22.9M	24.0M
Other Stockholder Equity	394.0M	379.2M	292.3M	293.9M	318.6M	264.1M
Total Liab	621.2M	756.5M	880.6M	869.7M	940.4M	987.4M
Property Plant And Equipment Gross	28.1M	117.2M	216.6M	220.2M	368.6M	350.2M
Total Current Assets	350.6M	362.0M	356.7M	389.0M	496.9M	521.8M
Short Term Debt	37.7M	40.5M	44.2M	49.0M	62.6M	65.7M
Current Deferred Revenue	261.1M	60M	295.2M	20.4B	23.5B	24.6B
Other Liab	5.9M	33.6M	5.0M	25.2M	29.0M	30.5M
Other Assets	12K	174.6M	73.3M	39.3M	45.2M	47.5M
Long Term Debt	232.3M	204.5M	432.1M	419.4M	361.9M	380.0M
Treasury Stock	(251.2M)	(319.1M)	(435.9M)	(461.2M)	(415.1M)	(394.3M)
Property Plant Equipment	28.1M	23.7M	119.7M	16.0M	18.4M	17.5M
Good Will	658.5M	932.7M	1.2B	1.3B	1.2B	1.3B
Intangible Assets	64.7M	74.2M	111.2M	101.2M	102.7M	64.1M
Net Tangible Assets	(82.8M)	(197.6M)	(375.9M)	(337.0M)	(303.3M)	(288.1M)
Noncontrolling Interest In Consolidated Entity	1.1M	1.5M	45.0M	55M	63.3M	66.4M
Retained Earnings Total Equity	246.4M	430.0M	639.1M	757.7M	871.3M	914.9M
Long Term Debt Total	232.3M	204.5M	432.1M	419.4M	482.3M	506.4M

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Amedisys in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Amedisys' short interest history, or implied volatility extrapolated from Amedisys options trading.

Pair Trading with Amedisys

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Amedisys position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Amedisys will appreciate offsetting losses from the drop in the long position's value.

Moving together with Amedisys Stock

0.82	GH	Guardant Health Financial Report 14th of May 2024	Pair Corr
0.64	IDXX	IDEXX Laboratories Financial Report 7th of May 2024	Pair Corr

Moving against Amedisys Stock

0.71	HCWB	HCW Biologics	Pair Corr
0.66	ELYM	Eliem Therapeutics Upward Rally	Pair Corr
0.65	ACB	Aurora Cannabis Sell-off Trend	Pair Corr
0.62	ELEV	Elevation Oncology Earnings Call This Week	Pair Corr
0.6	CGC	Canopy Growth Corp Financial Report 27th of June 2024	Pair Corr

The ability to find closely correlated positions to Amedisys could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Amedisys when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Amedisys - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Amedisys to buy it.

The correlation of Amedisys is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Amedisys moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Amedisys moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Amedisys can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Amedisys is a strong investment it is important to analyze Amedisys' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Amedisys' future performance. For an informed investment choice regarding Amedisys Stock, refer to the following important reports:

How To Invest In Amedisys

Details

Is Amedisys Stock a good investment?

Details

What is Amedisys' Net Worth?

Details

Largest Health Care Providers & Services Companies

View

Largest Health Care Equipment & Services Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Amedisys. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in income.

For information on how to trade Amedisys Stock refer to our How to Trade Amedisys Stock guide.

Note that the Amedisys information on this page should be used as a complementary analysis to other Amedisys' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.

Complementary Tools for Amedisys Stock analysis

When running Amedisys' price analysis, check to measure Amedisys' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amedisys is operating at the current time. Most of Amedisys' value examination focuses on studying past and present price action to predict the probability of Amedisys' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Amedisys' price. Additionally, you may evaluate how the addition of Amedisys to your portfolios can decrease your overall portfolio volatility.

	Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format
	Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
	Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
	Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators
	Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
	Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios

Is Amedisys' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Amedisys. If investors know Amedisys will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Amedisys listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.43)

Earnings Share

(0.64)

Revenue Per Share

69.004

Quarterly Revenue Growth

0.027

Return On Assets

0.0626

The market value of Amedisys is measured differently than its book value, which is the value of Amedisys that is recorded on the company's balance sheet. Investors also form their own opinion of Amedisys' value that differs from its market value or its book value, called intrinsic value, which is Amedisys' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Amedisys' market value can be influenced by many factors that don't directly affect Amedisys' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Amedisys' value and its price as these two are different measures arrived at by different means. Investors typically determine if Amedisys is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Amedisys' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Amedisys Operating Income vs Interest Income Analysis

Operating Income vs Interest Income

Operating Income vs Interest Income Correlation Analysis

Correlation Coefficient

Operating Income

Interest Income

Amedisys fundamental ratios Correlations

Amedisys Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Amedisys fundamental ratios Accounts

Pair Trading with Amedisys

Moving together with Amedisys Stock

Moving against Amedisys Stock

Complementary Tools for Amedisys Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Non Current Liabilities Total	+ 1.0	Short Long Term Debt Total
Non Currrent Assets Other	+ 1.0	Other Current Liab
Cash And Short Term Investments	+ 1.0	Cash
Common Stock	+ 1.0	Common Stock Total Equity
Total Stockholder Equity	+ 0.99	Total Assets
Non Current Assets Total	+ 0.99	Total Assets

Non Currrent Assets Other	- 0.5	Net Debt
Net Debt	- 0.48	Other Current Liab
Current Deferred Revenue	- 0.46	Non Currrent Assets Other
Current Deferred Revenue	- 0.44	Other Current Liab
Non Current Liabilities Total	- 0.43	Non Currrent Assets Other
Non Currrent Assets Other	- 0.43	Accounts Payable